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Abstract
Background: Antibiotic resistance is an increasing challenge for health care services worldwide. While up to 90%
of antibiotics are being prescribed in the outpatient sector recommendations for the treatment of community-
acquired infections are usually based on resistance findings from hospitalized patients. In context of the EU-project
called “APRES - the appropriateness of prescribing antibiotic in primary health care in Europe with respect to
antibiotic resistance” it was our aim to gain detailed information about the resistance data from Austria in both the
scientific and the grey literature.
Methods: A systematic review was performed including scientific and grey literature published between 2000 and
2010. Inclusion and exclusion criteria were defined and the review process followed published recommendations.
Results: Seventeen scientific articles and 23 grey literature documents could be found. In contrast to the grey
literature, the scientific publications describe only a small part of the resistance situation in the primary health care
sector in Austria. Merely half of these publications contain data from the ambulatory sector exclusively but these
data are older than ten years, are very heterogeneous concerning the observed time period, the number and
origin of the isolates and the kind of bacteria analysed. The grey literature yields more comprehensive and up-to-
date information of the content of interest. These sources are available in German only and are not easily
accessible. The resistance situation described in the grey literature can be summarized as rather stable over the last
two years. For Escherichia coli e.g. the highest antibiotic resistance rates can be seen with fluorochiniolones (19%)
and trimethoprim/sulfamethoxazole (27%).
Conclusion: Comprehensive and up-to-date antibiotic resistance data of different pathogens isolated from the
community level in Austria are presented. They could be found mainly in the grey literature, only few are
published in peer-reviewed journals. The grey literature, therefore, is a very valuable source of relevant information.
It could be speculated that the situation of published literature is similar in other countries as well.
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Background
The increasing prevalence of antibiotic resistance (AR)
is one of the major challenges for the healthcare systems
worldwide. Antibiotic resistant infections are associated
with a 1.3 to 2-fold increase in mortality compared to
antibiotic susceptible infections [1]. If antibiotics
become ineffective, infectious diseases will lead to an
increase in morbidity and eventually premature mortal-
ity [2-4]. Moreover, AR imposes enormous health
expenditure from higher treatment costs and longer
hospital stays [5-10]. In addition, the development of
new generations of antibiotic drugs is stalling [11].
Therefore, restrictive and appropriate use of antibiotics
is even more needed to ensure the availability of effec-
tive treatment of bacterial infections. While up to 90%
of antibiotics are being prescribed to patients in the out-
patient sector existing infor m a t i o no nt h ea n t i b i o t i c
resistance pattern is, with exceptions, based on samples
from hospitalized patients [12]. Excessive use of antibio-
tics by humans, mainly due to antibiotic overtreatment
of viral infections and in livestock breeding has led to a
large output of resistant bacteria into the environment,
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minate [13,14]. And indeed, the highest bacterial resis-
tances rate was found where antibiotics are used most
[12].
Two European initiatives provide valuable information
on the topic “antibiotic resistance” in Austria: EARS-Net
(formerly EARSS, European Antimicrobial Resistance
Surveillance System) [15] and ESAC (European Surveil-
lance of Antimicrobial Consumption) [16]. EARS-Net e.
g. performs a continuous surveillance of antimicrobial
susceptibility on the basis of laboratory analyses of inva-
sive, blood-culture derived isolates from hospitalized
patients. However, the antibiotic resistance pattern of
the microbial flora of hospitalized patients differs from
that seen in the community and, in addition, the resis-
tance pattern of bacteria in routine primary health care
is usually only tested after initial treatment failure [17].
Guidelines for prescribing antibiotics to patients at a
community level should, therefore, be based on empiri-
cal and up to date evidence about antibiotic resistance
of bacteria circulating in the community. Ideally, contin-
uous surveillance of resistance patterns and antibiotic
consumption in the outpatient setting should be carried
out to detect changes.
In the year 2010 an EU-project called “APRES - the
appropriateness of prescribing antibiotics in primary
health care in Europe with respect to antibiotic resis-
tance” started in nine European countries including
Austria. One aim of this cross-sectional project is a sys-
tematic analysis of antibiotic resistance pattern of two
key-bacteria at the community level. The analysis should
be the basis for specific regional and national recom-
mendations concerning the antibiotic prescribing beha-
viour of physicians in primary health care.
In the context of this EU-study we have undertaken a
systematic literature review of all scientific papers and
also of grey and non-English literature concerning the
resistance pattern for the primary care sector in Austria
in order to summarize existing facts and knowledge. It
was our aim to assess strengths and weaknesses of the
resistance situation at the community level described for
Austria and to identify the sources and origin of the
data published.
Methods
Study selection
A systematic literature review was performed of all
available literature published between the 1
st of January
2000 and the 31
st January 2011. For the review process
we followed the recommendations of the PRISMA (Pre-
ferred Reporting Items for Systematic Reviews and
Meta- Analyses) statement [18] as it is described in the
additional file 1. Three necessary inclusion criteria for
the relevant literature were defined: First, the content
has to deal with antibiotic resistance. Second, the resis-
t a n c ed a t ah a v et ob es a m p l e di nt h ea m b u l a t o r yo r
community sector in humans and third, in Austria. We
searched the scientific literature as well as the grey
literature.
All types of indexed scientific literature were included.
T h eb a c t e r i ai n c l u d e dw e r eStreptococcus pyogenes,
Streptococcus pneumoniae, Haemophilus influenzae,
Moraxella catarrhalis, Klebsiella pneumoniae for the
respiratory tract, Escherichia coli, Proteus mirabilis,
Klebsiella spp., Staphylococcus saphrophyticus for the
urinary tract and Staphylococcus aureus. Literature con-
taining resistance data from the hospital setting only
and the literature not describing the origin either from
hospital or primary care setting of the samples were
excluded. The language of the literature included was
English and German.
For the specification of the “grey” literature we used
the definition of the Luxembourg Convention on Grey
Literature: “Grey literature is that which is produced on
all levels of government, academics, business, and indus-
try in print and electronic formats but which is not con-
trolled by commercial publishers.” [19] Essentially, grey
literature includes documents that have not been for-
mally published in a peer-reviewed indexed format.
The literature search via electronic searches as well as
the review process was carried out by two researchers
(KH and GW) for the inclusion and exclusion criteria.
Disagreement within the review process was resolved by
discussion with the fourth author (MM).
Search strategy
The literature search was performed during the period
from April 1, 2010 until March 29, 2011.
For the scientific literature the databases and search
engines PubMed, Medline and Embase were used.
Search terms were the MeSH (Medical Subject Head-
ings) terms “primary health care” OR “ambulatory care”
AND “drug Resistance, Bacterial” AND “Austria” which
were combined with the search terms “antibiotic resis-
tance” OR “antimicrobial resistance”, “primary care” OR
“outpatient” OR “general practice” OR “community”,i n
different combinations. According to the terms in Eng-
lish we used the corresponding German terms “Antibio-
tika”, “Resistenzen”, “Allgemeinmedizin”,
“niedergelassener Bereich” and “Österreich”. Addition-
ally, manual searches of the references of relevant arti-
cles including reviews were performed.
The search strategy for the grey literature was con-
ducted via the search engines Google (http://www.goo-
gle.at) and Google Scholar (http://scholar.google.at); in
addition a systematic search on websites of institutions
and organizations dealing with the sampling and deter-
mination of bacteria like regional laboratories for
Hoffmann et al. BMC Infectious Diseases 2011, 11:330
http://www.biomedcentral.com/1471-2334/11/330
Page 2 of 13infectious diseases, reference centres or organizations
that are responsible for public health like the Ministry
of Health and linked facilities was performed. The
search terms used were the same as for the scientific
literature.
The exclusion process for the scientific literature was
a three step process. The first step was the rejection of
the duplicates, followed by the exclusion due to screen-
ing the title and abstract of papers identified; in the
third step the papers were excluded by reading the full
text of the papers, each of which was independently
reviewed for eligibility. The exclusion process for the
grey literature was performed as a three step process
too by reading the “Google” title of the link and the
short description first, followed by reading the full text
of the relevant literature.
Finally, we allocated the literature that met all inclu-
sion criteria into a “high quality” group (reports, govern-
ment documents, recommendations of Austrian
Societies, publications not published in an indexed jour-
nal) with respect to the method section described in this
literature and a “low quality group” (interviews, official
invitations, meeting notes) as recommended by Dobbins
et al [20]. Only the “high quality” grey literature was
included into this review.
Data extraction
The outcome data extracted were: Numbers and charac-
teristics of the included studies, bacteria types described,
sampling location in Austria and general antibiotic resis-
t a n c ef i n d i n g s .F u r t h e r ,t h es o u r c e so ft h ed a t aw e r e
documented.
Results
After the rejection of the duplicate papers a total of 82
potential scientific papers were identified of which 9
were excluded on the basis of the year published and 40
were excluded after reading the abstract and title.
Further 16 papers were excluded after reading the full
text. Most of the papers were excluded because the
reported incidence of resistance data was exclusively
from the hospital sector in Austria (EARS-Net) or other
countries than Austria. Seventeen papers were included
into the final review. Figure 1 shows the “PRISMA Flow
Diagram” for the scientific literature results [18]. The
grey literature search strategy yielded e.g. 3,840 potential
relevant links on March, 29 2011 by using the combina-
tion of the search terms “Antibiotikaresistenzen” AND
“Österreich” AND “niedergelassener Bereich” in Google.
at. After the three step review procedure 23 high quality
publications remained of which 21 are resistance reports
(19 regional reports from different years published
between 2002 and 2011 and two national reports of the
years 2008 and 2009). Most of the excluded literature
enunciated treatment recommendations of infectious
diseases for the ambulatory sector by referencing to data
from the hospital sector.
Table 1 summarizes the basic characteristics and
selected resistance findings of the final 17 scientific
papers. Nine [21-29] out of the 17 scientific papers
describe the resistance pattern of certain bacteria for the
ambulatory sector only by referencing to four data
sources, the Alexander-Project [22,27], the PROTEKT
(Prospective Resistant Organism Tracking and Epide-
miology for the Ketolide Telithromycin) surveillance
study [21,23,25], the ECO-SENS (International Survey of
the Antimicrobial Susceptibility of Urinary Pathogens)
project [24,26,29] and the ARESC (Antimicrobial Resis-
tance Epidemiological Survey on Cystitis) study [28].
Eight of these nine publications describe the resistance
situation in Austria before the year 2001. The reported
resistance patterns of the analysed bacteria in the other
publications are based on isolates from both the hospital
and the outpatient sector in different proportions.
Six articles show the resistance pattern of E. coli,
ESBL-producing E. coli and other bacteria related to
community-acquired uncomplicated urinary tract infec-
tions [24,26,28-31], eight the resistance pattern of the
bacteria included for community-acquired respiratory
tract infections [21-23,25,27,32-34], further two are deal-
ing with the MRSA s i t u a t i o ni nA u s t r i a[ 3 5 , 3 6 ]a n do n e
article is a “letter to the editor” with an overview of
multiple bacteria [37]. No overall conclusion of the cur-
rent resistance situation in the ambulatory sector in
Figure 1 PRISMA Flow Diagram. The flowchart is showing the
search strategies and the exclusion criteria used to locate the
relevant scientific studies in this review.
Hoffmann et al. BMC Infectious Diseases 2011, 11:330
http://www.biomedcentral.com/1471-2334/11/330
Page 3 of 13Table 1 Basic characteristics and general resistance findings of the final 17 scientific papers (in alphabetical order)
Author Sampling
setting and
report of results
Sampling
location
Years of
resistance
testing
Total no.
of isolates
(Austria)
Bacteria Antibiotics General Resistance findings
Auer et al
2010 [30]
Hospital (2%) and
primary health
care (98%) -
results reported
together
Salzburg, Upper
Austria, Styria
(Austria)
2004-2008 100 ESBL-
producing E.
coli
FOF, MEL,
ETP, NIT,
SXT, GEN,
CIP
3% FOF, 6% NIT, 15% MEL, 0% ETP,
22% GEN, 73% SXT, 78% CIP
a
Badura et al
2007 [37]
Hospital and
primary health
care- results
reported together
Southeast
Austria
1997-2006 690,967
collectively
E. coli, S.
aureus,
Klebsiella spp.
Various for
each
bacteria
The data show insignificant changes
in prevalence of MRSA and
vancomycin-resistant enterococci in
southeast Austria during the past
decade (1997-2006) but an alarming
increase of ESBL-producing E. coli
isolates in recent years.
Buxbaum et
al 2003 [32]
Hospital and
primary health
care- results
reported together
Austria 2001-2002 542 S.
pneumoniae,
PEN, TEL,
ERY, CLR,
2.2% PEN, 0% TEL, 8.5% ERY, 10.3%
CLR, 7% AZM
223 S. pyogenes, same 0% PEN, 0% TEL, 8% ERY, 6.7% CLR,
8.1% AZM
183 S. aureus, same 73.2% PEN, 2.2 TEL, 17% ERY, 16.4%
CLR, 16.4% AZM
67 H. influenzae AMP instead
of PEN
1.5% AMP, 0% TEL, ERY, CLR, AZM
Canton et al
2002 [21]
Primary health
care
25 countries
worldwide incl.
Austria
1999-2000 25 S.pyogenes, ERY, LVX,
PEN, TEL
No special results for Austria. But
compared to the other countries
Austria had one of the lowest
resistance rates.
20 S.aureus TEL 0% TEL
Cizman 2003
[22]
Primary health
care
21 countries in
Europe incl.
Austria
1997-1999
1997-2000
n/a H. influenzae, PEN The antibiotic resistance rates were set
in correlation with the mean national
outpatient consumption. Compared to
the other countries Austria had a low
total outpatient consumption of 13.80
DDD/1000 inhabitants/day in 1997
and a penicillin resistance rate of S.
pneumoniae of 12.4%. With the
consumption of macrolides Austria
was ranked in the middle field with a
resistance rate for S. pneumoniae of
11.4%.
S.
pneumoniae,
PEN, ERY
S. pyogenes ERY
Felmingham
et al 2002
[23]
Primary health
care
25 countries
worldwide incl.
Austria
1999-2000 57 S.
pneumoniae
PEN, ERY 5.3% PEN, 12.3% ERY
Compared to the other countries
Austria had one of the lowest
resistance rates.
Graninger
2003 [24]
Primary health
care
16 European
countries incl.
Austria and
Canada
1999-2000 n/a E. coli n/a The publication highlights the
effectiveness of MEL compared to
other antibiotics
Hoban et al
2002 [25]
Primary health
care
25 countries
worldwide incl.
Austria
1999-2000 40
19
H.influenzae
M. catarrhalis
n/a 2.5% ß-lactamase +
89.5% ß-lactamase +
Hönigl et al
2010 [33]
Hospital (63%)
and primary
health care (37%)-
results reported
together
Southeast
Austria
1997-2008 1997: (n =
113) 2008:
(n = 218)
S.
pneumoniae
PEN, ERY,
CLI, TET,
SXT,
quinolones
1997: 3.5% ERY, 1.8% CLI, 1.8% TET,
7.1% SXT, 0.9% QUIN
2008: 14.7% ERY, 10.6% CLI, 11% TET,
9.2% SXT, 0.5% quinolones
Hoffmann et al. BMC Infectious Diseases 2011, 11:330
http://www.biomedcentral.com/1471-2334/11/330
Page 4 of 13Table 1 Basic characteristics and general resistance findings of the final 17 scientific papers (in alphabetical order)
(Continued)
Kahlmeter
2003 [26]
Primary health
care
17 countries in
Europe incl.
Austria
1999-2000 126 E. coli AMP, AMC,
MEC,
CFR, TMP,
SUL, SXT,
NAL, CIP,
NIT, FOF,
GEN
Compared to the other 16 European
countries Austria had one of the
lowest resistance rates for E. coli:
17.5% AMP, 2.4% AMC, 1.6% MEC,
0.8% CFR, 9.5% TMP, 25.4% SUL, 9.5%
SXT, 2.4% NAL, 0% CIP, 0.8% NIT, 0%
FOF, 0.8% GEN
Kahlmeter et
al 2003 [29]
Primary health
care
17 countries in
Europe
including
Austria
1999-2000 126 E. coli AMP, AMC,
MEC,
CFR, TMP,
SUL, SXT,
NAL, CIP,
NIT, FOF,
GEN
17.5% AMP, 2.4% AMC, 1.6 MEC, 0.8%
CFR, 9.5% TMP, 25.4 SUL, 9.5% SXT,
2.4% NAL, 0% CIP, 0.8% NIT, 0% FOF,
0.8 GEN
Krziwanek et
al 2008 [35]
Hospital and
primary health
care- results
reported together
Austria 1996-2006 1,439 MRSA n/a In Carinthia, 73% of all MRSA
belonged to ST228. In the Austrian
region “Salzkammergut”, the
proportion of ST5 increased from 26%
in 2004 to 89% in 2006. In eastern
Upper Austria and western Lower
Austria, the ST8 Austrian clone was
predominant.
Krziwanek et
al 2009 [36]
Hospital and
primary health
care- results
reported together
Upper Austria 2006-2008 1,098 MRSA n/a Out of the 1,098 MRSA samples from
humans, 21 were MRSA type ST398
that is usually associated with animals.
Most of these 21 patients were
farmers (n = 16). Increasing prevalence
from 1.3% in 2006 to 2.5% in 2008
shows emergence of MRSA ST398 in
humans in Austria.
Prelog et al
2008 [31]
Hospital and
primary health
care- results
reported together
Western Austria 2006 2,042 E. coli n/a 20 out of the 2,042 E. coli isolates
demonstrated alleles encoding CTX-M
enzymes belonging to phylogentic
group 1.
Schito et al
2000 [27]
Primary health
care
14 countries in
Europe incl.
Austria
1992-1998 185 S.
pneumoniae
PEN, ERY 4.8% PEN, 11.4%
153 H. influenzae DOX, SXT,
CIP
1.3% DOX, 13.7% SXT, 0.0% CIP
n/a M. catarrhalis n/a
Schito et al
2002 [34]
Hospital and
primary health
care- results
reported together
Italy, Spain,
Austria
1999-2000 3,593
collectively
in all three
countries
S.
pneumoniae,
M. catherrralis,
H. influenzae
K.
pneumoniae
S. pyogenes,
S. aureus
AMP, AMC,
CEC, CXM,
CFM, CTB,
CPD, AZM,
CLR
for all
bacteria
The results show a substantial
prevalence of macrolide resistance of
the bacteria analysed in Italy, Spain
and Austria.
Schito et al
2009 [28]
Primary health
care
9 European
countries
including
Austria and in
addition Brazil
2003-2006 3,018
collectively
in all nine
countries
E. coli, K.
pneumoniae,
P. mirabilis, S.
saphrophyticus
AMP, AMC,
MEC, CFX,
NAL, CIP,
SXT, NIT,
FOF
Mean resistance rates for E.coli
between 2003 and 2006 for Austria
were e.g.: 48.3% AMP 8.1% NAL and
29.0% SXT. Compared to the other
countries Austria with 48.3% resistance
against AMP had one of the highest
resistance rates; against the other
antibiotics one of the lowest rates.
Abbr.: FOF, fosfomycin; MEL, pivmecillinam; ETP, ertapenem; NIT, nitrofurantoin; GEN, gentamicin; SXT, trimethoprim-sulfamethoxazole; CIP, ciprofloxacin; PEN,
penicillin; ERY, erythromycin; CLI, clindamycin; TET, tetracycline; AMP, ampicillin; AMC, co-amoxiclav; MEC, mecillinam; CFR, cefadroxil; TMP, trimethoprim; SUL,
sulfamethoxazole; NAL, nalidixic acid; DOX, doxycyclin; CXM, cefuroxime; CEC, cefaclor; CFM, cefixime; CTB, ceftibuten; CPD, cefpodoxime; AZM, azithromycin; CLR,
clarithromycin; LVX, levofloxacin
n/a: Data not described in the publication
a: Resistance data include intermediate susceptible isolates
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due to the differences in sampling settings, inclusion
and exclusion criteria of the study population, time peri-
ods, bacteria analysed and the methodology used. More-
over, the determination of the resistance rates in Austria
was conducted using the CLSI (Clinical and Laboratory
Standards Institute) standard. Within this standard there
has been a change in the antimicrobial MIC breakpoint
in 2008 which means that most data before and after
2008 are not comparable [38].
Tables 2 and 3 summarize the basic characteristics
and selected resistance findings of the 23 high quality
grey literature documents of which only the isolates
from the primary health care sector included into the
reports are described. The resistance findings included
are contained in several reports and their updates
since the year 2008 separately for the ambulatory and
the hospital sector. The key-bacteria analysed for the
urinary and respiratory tract are the same among the
reports. The Austrian resistance reports (AURES) of
the years 2008 and 2009 e.g. include the chapter
“Resistance report for selected non-invasive microbial
pathogens” w h i c hs u m m a r i z et h ed a t af r o mt h ea m b u -
latory sector of several large microbiology laboratories
from all over Austria; a change in the resistance pat-
tern of the bacteria included can be observed in cer-
tain regions over several years (table 3). While the
change in the CLSI standard in 2008 has to be consid-
ered for these resistance reports as well the overall
resistance situation in the primary care sector in Aus-
tria for e.g. E. coli is summarized as following: “The
percentage of the ESBL-producing E. coli is with 6%
stable over the last two years in the primary care sec-
tor. The highest antibiotic resistance rates for E. coli
and ESBL-producing E. coli can be seen with fluorochi-
nolones (19%/85%) and trimethoprim/sulfamethoxazole
(27%/82%).”[39]
All resistance reports included are published in Ger-
man only and on special websites.
Discussion
This review provides the most comprehensive and up to
date information on the pattern of AR at the commu-
nity level in Austria. This has been achieved by a thor-
ough search of both the scientific and grey literature.
Our analysis shows that the seventeen scientific publi-
cations included describe only a small part of the resis-
tance situation in the primary health care sector in
Austria (table 1). Half of these publications contain data
from the ambulatory sector only but are older than ten
years. Moreover, the included scientific literature is very
heterogeneous concerning the observed time period, the
number and origin of the isolates and the kind of bac-
teria analysed.
In contrast, the grey literature yields more substantial
information on the content of interest (tables 2 and 3).
Mainly the “resistance reports” (Resistenzberichte) con-
tain comprehensive and up-to-date resistance data from
the ambulatory level. Since 2008, the AURES report in
particular is the only source which provides comprehen-
sive, structured and nationwide data on a yearly basis
from isolates obtained exclusively at the primary care
sector. The resistance situation described can be sum-
marized as rather stable over the last two years. A com-
parison of the resistance situations can be drawn on a
regional and on a national level (table 3). This literature
is at the moment the best available source of ambulatory
resistance data; however, the data are not covering all
regions of Austria. Further, the reports are available in
German only, are accessible on certain specific websites
only and are not published in indexed journals. There-
fore, it is nearly impossible for someone who cannot
speak German or is not familiar with the website
address to find a comprehensive source of information
about the current resistance situation in the primary
health care sector in Austria. Moreover, the methodol-
ogy for the determination of resistance differs between
Austrian counties and European countries which, hope-
fully, will improve due to the EUCAST (European Com-
mittee on Antimicrobial Susceptibility Testing) efforts to
harmonize the MIC breakpoints for antimicrobial sus-
ceptibility testing of bacteria in Europe [40]. This could
be an obstacle for comparative studies which are based
on systematic literature searches from different coun-
tries or for finding adequate sources to describe the sta-
tus quo in Austria. Unfortunately, the results from the
promising international studies (Alexander project and
PROTEKT study)[41] of the years 1999 and 2000 that
dealt with the resistance pattern of bacteria responsible
for community-acquired infections of the respiratory
tract have not been translated into regular national or
international surveillance systems.
In contrast, comprehensive and current antibiotic
resistance data from the hospital sector or outpatient
antibiotic consumption data in Austria are easy to find
in the scientific literature due to the longstanding part-
nership of Austria with the EARS-Net and ESAC net-
work. These standardized data were collected
nationwide and published regularly [42,43]. This could
be the reason that, at the moment, all recommendations
available for the treatment of community-acquired infec-
tious diseases for the primary health care sector still are
based on resistance data derived from the hospital sec-
tor [44]. Examples are the brochure of the Austrian
Antibiotic Stewardship Group (ABS) for the ambulatory
sector or the latest expert consensus of the Austrian
Society of Infectious Diseases concerning Antibiotic
treatment in primary health care [45,46]. It should be
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Editor Title Sampling
setting and report of the results
Sampling
location
Tested
bacteria
Years of
sampling
and
resistance
testing
Bundesministerium
f. Gesundheit
Österreich
Österreichischer Resistenzbericht
AURES 2009 [39]
Hospitals and primary health care sector -
results reported separately
Austria S. pyogenes,
S.
Pneumoniae
H.influenzae
E. coli, P.
mirabilis,
S. aureus
One year
before the
publication
Österreichischer Resistenzbericht
AURES 2008 [61]
Abt. f.
Mikrobiologie,
Med.-chem. Labor
Dr. Mustafa, Labor
Dr. Richter OG
Resistenzreport 2009
Zusammenfassung der lokalen
Resistenzdaten [62]
The majority of isolates was collected in the
primary health care sector but some isolates
were collected in hospitals and residencies as
well - results reported partly separate since
2009
Salzburg,
Upper
Austria,
Upper Styria
(Austria)
S. pyogenes,
S.
pneumoniae
H.
influenzae
E. coli, P.
mirabilis,
S. aureus
One year
before the
publication
Resistenzreport 2008
Zusammenfassung der lokalen
Resistenzdaten [63]
Resistenzbericht 2007 [64]
Resistenzbericht 2006 [65]
Resistenzbericht 2005 [66] Salzburg
(Austria)
Resistenzbericht 2004 [67]
Resistenzbericht 2003 [68]
Resistenzbericht 2002 [69]
Institut f. Hygiene,
Mikrobiologie und
Umweltmed.
Med. Univ. Graz,
Labor für Med.
Bakteriologie und
Mykologie
Resistenzbericht 2010 [70] Isolates from primary health care (50%) and
from secondary and tertiary care sector (50%)
- results reported partly separate
Styria
(Austria)
S. pyogenes,
S.
pneumoniae
H.
influenzae
E. coli, P.
mirabilis,
S. aureus
One year
before the
publication
Resistenzbericht 2009 [71]
Resistenzbericht 2008 [72]
Bakterielles Labor
des LKH Leoben
Resistenzbericht 2009 aus dem
Einsendegut des Bakt. Labors im
LKH Leoben [73]
Hospitals (90%) and primary health care
(10%) - results reported partly separate since
2007
Upper Styria
(Austria)
S. pyogenes,
S.
pneumoniae
H.
influenzae
E. coli, P.
mirabilis,
S. aureus
One year
before the
publication
Resistenzbericht 2007 aus dem
Einsendegut des Bakt. Labors im
LKH Leoben [74]
Resistenzbericht 2006 aus dem
Einsendegut des Bakt. Labors im
LKH Leoben
Resistenzbericht 2005 aus dem
Einsendegut des Bakt. Labors im
LKH Leoben [75]
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Location Pathogen Tested isolates Antibiotics Resistance in % Additional information
2009 and 2008 AURES [39,61]Bundesministerium f. Gesundheit Österreich
2008 2009 2008 2009 2008 2009
Respiratory tract S. pyogenes 977 1,440 PEN 0 0
1,436 1,433 macrolides 3.6 3.3
1,438 1,356 fluoroquinolones 0.7 0.3
S. pneumoniae 510 454 PEN 0.8 1.8
510 454 macrolides 14.5 13.4
506 455 fluoroquinolones 0.8 0.2
H. influenzae 1,244 1,255 AMP or AMX 9.4 9.6
1,244 1,255 AMC 0 0.1
1,244 1,234 fluoroquinolones 0.2 0
All locations S. aureus 2,395 3,970 OXA 2.4 2.1 MRSA
2.4%
MRSA
2.1%
2,994 3,746 macrolides 14.5 14.9
3,045 3,757 CLI 6.9 9.7
3,277 3,547 SXT 0,8 0.6
1,633 3,886 fluoroquinolones 3.8 3.6
Urinary tract E coli 8,992 11,218 AMP or AMX 39.8 43.9 ESBL
6.0%
ESBL
6.4%
8,985 11,219 AMC 5.8 9.2
9,088 11,107 cephalosporin 1
st 8.5 9.7
8,992 11,225 SXT 24.6 27.5
8,992 11,241 fluoroquinolones 15.7 18.8
8,789 10,738 NIT 2.2 2.7
4,361 4,893 MEL 12.2 6.8
5,489 7,799 FOF 1.5 2.3
P.mirabilis n/a n/a
Location Pathogen Tested isolates Antibiotics Resistance in % Additional information
2010 Medical University Graz, Department for Hygiene and Microbiology [70]
Respiratory tract S. pyogenes n/a
S. pneumoniae n/a
H. influenzae n/a
S. aureus 444 OXA 2.5 MRSA
2.5%
441 SXT 0
434 CIP 3
444 ERY 14.9
444 CLI 13.7
Urinary tract E. coli 3,907 AMX 61.4 ESBL
7.4%
3,907 AMC 37.5
3,902 CFX 6.3
3,907 TMP 27.6
3,907 SXT 27.2
3,881 FOF 0.8
3,907 CIP 18.5
3,905 NIT 0.4
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(Continued)
2009 Laboratory Dr Richter and Dr Mustafa, Section for Microbiology, Salzburg [62]
Respiratory tract S. pyogenes n/a
S. pneumoniae n/a
H. influenzae n/a
Skin and soft tissue S. aureus 938 OXA 3 MRSA
3%
938 AMC 3
938 CFX 3
938 ERY 13
938 CLIN 3
938 SXT 1
938 MXF 3
Urinary tract E. coli 2,506 AMP 40 ESBL
4%
2,506 AMC 6
2,506 CFX 6
2,506 SXT 26
2,499 NIT 1
2,506 CIP 16
2,504 FOF 1
P. mirabilis n/a
2009 Medical University Innsbruck, Section for Hygiene and Medical Microbiology [78]
Respiratory tract S. pyogenes 187 PEN 0
187 AZM 5.8
187 MXF 2.1
S. pneumoniae 115 PEN 0
115 AZM 12.1
115 MXF 0.87
H. influenzae 76 AMP 25
76 AMC 0
76 MXF 0
All locations S. aureus 676 FOX 1.48 MRSA
6%
610 AZM 20.9
610 CLIN 18
674 SXT 1.03
609 MXF 1.97
Urinary tract E. coli 3,112 AMP 58 ESBL
9%
3,104 AMC 20
3,101 CFZ 17
3,112 SXT 33
3,112 CIP 26
3,097 MEC 7
3,111 NIT 7
2009 County Hospital Leoben, Bacteriological Laboratory [73]
Respiratory tract S. pyogenes n/a
S. pneumoniae n/a
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Page 9 of 13mentioned that first steps towards a resistance-register
for non-invasive isolates from the primary health care
sector in Austria are already under way. The collection
and reporting of non-invasive isolates and their resis-
tances in the regional and the national resistance reports
in a structured and systematic way could be the starting
point. Also the ABS group is advancing this issue
[47,48].
The strengths of this review are its focus on the out-
patient setting in Austria and its comprehensiveness by
the inclusion of both the scientific and the grey litera-
ture. In fact, for our purpose the data contained in the
grey literature prove very valuable in achieving our aim
of comprehensiveness and reduces publication and
selection bias. It could be speculated that the situation
of published literature is similar in other countries as
well. However, recent studies have examined the impact
of the inclusion of the grey literature in systematic
reviews to describe the status quo of a situation in more
detail [49-51]. Especially, since a Cochrane update was
published in 2004 to highlight the importance of wide-
spread literature search strategies for public health inter-
ventions including the grey literature for systematic
reviews [52] the number of reviews which include grey
literature is growing constantly in many health related
sectors [53-60].
The limitations of this literature review are the reli-
ance on previously published research results. Even
more difficult is the reliance on the grey literature
found due to the non hierarchic search results with the
search engine Google. Moreover, in this review we com-
pared the scientific and the grey literature and draw
conclusions on their comprehensiveness and on the
public health relevance of their content. Since the scien-
tific papers were independently peer-reviewed and the
grey literature was published by organizations without
that review process this may affect the methodological
quality and therefore, the scientific level of evidence. In
addition, it is not possible to directly compare the resis-
tance data described in the scientific and grey literature:
Table 3 Selected resistance findings from the ambulatory sector only of the most up-to-date grey literature included
(Continued)
H. influenzae n/a
S. aureus 141 AMC 1.4
141 OXA 1.4
141 CFZ 1.4
140 CLIN 11.4
140 ERY 12.1
140 CIP 0.7
Urinary tract E. coli 310 AMP 41
310 AMC 10
310 CFZ 10.0
309 TMP 29.5
310 CIP 20,0
309 NIT 1.9
27 MEC 11.1
P. mirabilis 28 AMC 10.7
28 CFZ 17.9
28 TMP 53.6
28 CIP 17.9
Hell [80]
Urinary tract E. coli
ESBL-producing
100 MEC 11
100 FOF 3
100 NIT 1
100 SXT 73
100 CIP 78
Abbr.: FOF, fosfomycin; MEL, pivmecillinam; NIT, nitrofurantoin; SXT, trimethoprim-sulfamethoxazole; CIP, ciprofloxacin; PEN, penicillin; ERY, erythromycin; CLI,
clindamycin; AMP, ampicillin; AMX, amoxicillin; AMC, amoxicillin/clavulanate; MEC, mecillinam; TMP, trimethoprim; SUL, sulfamethoxazole; AZM, azithromycin; CFZ,
cefazolin; FOX, cefoxitin; OXA, oxacillin; MXF, moxifloxacin
n/a: Resistance data of isolates from primary care alone not available
Hoffmann et al. BMC Infectious Diseases 2011, 11:330
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Page 10 of 13in the scientific literature the resistance data are mainly
analysed for specific diseases like e.g. uncomplicated
urinary tract infections in a defined group of patients, in
the grey literature the resistance data reported are the
result of all isolates analysed for one specific bacterium
regardless of a given disease.
Conclusion
In this review, comprehensive and up-to-date antibiotic
resistance data of different pathogens, isolated from the
primary care level in Austria, are presented. They could
be found mainly in the grey literature, only few are pub-
lished in peer-reviewed journals. The grey literature,
therefore, is a very valuable source of relevant informa-
tion and might reveal possibilities for further research.
Based on these findings we recommend collecting and
publishing also the non-invasive resistance findings on a
regular basis in indexed journals like it is done in the
EARS-Net and ESAC network.
Additional material
Additional file 1: PRISMA 2009 checklist. Checklist including relevant
page numbers for identifying various components of the review.
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